alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
IN THE UNITED STATES DISTRICT COURT

FOR THE EASTERN DISTRICT OF TEXAS

MARSHALL DIVISION

HEADWATER RESEARCH LLC,

Plaintiff,

v.

T-MOBILE USA, INC. AND SPRINT CORP.,

Defendants.

Civil Action No. 2:23-cv-00379-JRG-RSP

HEADWATER RESEARCH LLC,

Plaintiff,

v.

T-MOBILE USA, INC. AND SPRINT CORP.,

Defendants.

Civil Action No. 2:23-cv-00377-JRG-RSP

ORDER ON DEFENDANTS’ MOTION FOR ENTRY OF AN ORDER FOCUSING 

ASSERTED PATENT CLAIM AND PRIOR ART

Before the Court is Defendants’ Motion for Entry of an Order Focusing Asserted Patent 

Claims and Prior Art. The Court, having considered same, is of the opinion the motion should be

and is hereby GRANTED and orders as follows: 

• Within 7 days of the issuance of this Order, Headwater shall immediately narrow to no 

more than 10 claims from each patent and not more than a total of 32 claims. 

• 28 days afterwards, T-Mobile shall narrow to no more than twelve prior art references 

against each patent and not more than a total of 40 references. 

• By 28 days before the service of opening expert reports, Headwater shall narrow to no 

more than five asserted claims per patent and no more than a total of 16 claims. 

Case 2:23-cv-00379-JRG-RSP Document 58-8 Filed 04/30/24 Page 1 of 2 PageID #: 749
• By the date for opening expert reports, T-Mobile shall narrow to no more than six 

asserted prior art references per patent and no more than 20 total references. 

It is so ordered. 

Case 2:23-cv-00379-JRG-RSP Document 58-8 Filed 04/30/24 Page 2 of 2 PageID #: 750
Victor Garry BAXTER, petitioner, v. UNITED STATES.

No. 18-6213.

Supreme Court of the United States

Nov. 5, 2018.

Petition for writ of certiorari to the United States Court of Appeals for the Eleventh Circuit denied.

Justice KAGAN took no part in the consideration or decision of this petition.
James M. FLINN, petitioner, v. Mike PARRIS, Warden.

No. 18-7110.

Supreme Court of the United States

Jan. 14, 2019.

Petition for writ of certiorari to the United States Court of Appeals for the Sixth Circuit denied.
EX-4.2.3





 Exhibit 4.2.3 

AMENDMENT NO. 3 TO THE PATENT LICENSE AGREEMENT NO. C-00061906 

BETWEEN: 
 L’Institut Pasteur, a public
interest foundation, 25, rue du Docteur Roux, 75015 Paris, represented by Mr. Jean Castex, adjunct General Manager for administration and finance, 

Hereafter referred to as “IP” or the “Licensor”, 

Party of the first part, 
 AND: 

CELLECTIS, CELLECTIS 
 Public limited company with capital
with a capital of 122,363.47 euros, with its registered office at 102, route de Noisy, 93235 Romainville cedex, represented by Mr. André Choulika, acting in the capacity of CEO 

Hereafter referred to as “CELLECTIS” or the “LICENSEE”, 

Party of the second part. 
 The LICENSOR and LICENSEE are
hereafter referred to as the “Parties”. 
 RECITALS: 

IP owns patents and patent applications relating to a method of homologous recombination. 

On June 19, 2000, the Parties signed license agreement no. C-00061906 (hereafter the “AGREEMENT”), by
which the LICENSOR grants the LICENSEE exploitation rights to the above mentioned patents and patent applications. 
 The AGREEMENT was the subject of a
first amendment signed on September 8, 2003 and a second amendment dated June 24, 2004 modifying the FIELD of the AGREEMENT. 
 After discussions
and exchanges between the Parties, they have decided to modify the provisions of the AGREEMENT. 
 It is thus agreed as follows: 

ARTICLE 1 
  

	1.1	 The Parties agree that the words defined in Article 1, “DEFINITIONS”, of the AGREEMENT, as they are
used in this amendment, have the same definitions as in the AGREEMENT and form an integral part of this amendment. 


 ARTICLE 2

 Article 1.3 of the AGREEMENT is modified by the following provisions, which supersede all previous provisions of the same article: 












 1.2 FIELD 

FIELD of the AGREEMENT covers the field of homologous recombination applied to all genes other than those that code for Erythropoietin
(EPO). 
 ARTICLE 3 
 Article 2.1 of the
AGREEMENT is modified by the following provisions, which supersede all previous provisions of the same article: 
 2.1 The LICENSOR
grants, under the terms and conditions specified herein, to the LICENSEE, who accepts this, an exclusive license for the AGREEMENT PATENTS under the AGREEMENT to make, have made, use and sell the LICENSED PRODUCTS and/or implement or have
implemented the LICENSED PROCESSES in the TERRITORY within the FIELD during the term of this AGREEMENT. 
 ARTICLE 4 

Under this Amendment, the LICENSEE will pay the LICENSOR, 60 days from the date of signature of this Amendment, a fixed,
non-refundable and non-deductible payment of 100,000 EUROS ex tax. 

ARTICLE 5 
 This Amendment will enter into force on
the date of its signature. 
 The AGREEMENT’s other provisions remain unchanged and in force between the Parties. 

 
  

			
	Signed in Paris on	  	             [Handwritten text:
August 24, 2005]

	in 2 original copies.	  	

  

			
	 CELLECTIS
	  	 INSTITUT PASTEUR
Joshua Donald EWING, petitioner, v. UNITED STATES.

No. 18-6935.

Supreme Court of the United States

Jan. 7, 2019.

Petition for writ of certiorari to the United States Court of Appeals for the Sixth Circuit denied.
Michael Rocky LANE, petitioner, v. UNITED STATES.

No. 18-6235.

Supreme Court of the United States

Nov. 13, 2018.

Petition for writ of certiorari to the United States Court of Appeals for the Ninth Circuit denied.
Hector PARRALES-GUZMAN, petitioner, v. UNITED STATES.

No. 17-8349.

Supreme Court of the United States

Oct. 1, 2018.

On petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit. Motion of petitioner for leave to proceed *in forma pauperis* and petition for writ of certiorari granted. Judgment vacated, and case remanded to the United States Court of Appeals for the Fifth Circuit for further consideration in light of *Sessions v. Dimaya,* 584 U.S. ----, 138 S.Ct. 1204, 200 L.Ed.2d 549 (2018).
N OTE : This disposition is nonprecedential. 

# United States Court of Appeals **for the Federal Circuit**

______________________

OCEAN DUKE CORPORATION, Plaintiff-Appellant,

v.

UNITED STATES, Defendant-Appellee.

____________________

2011-1597

______________________

Appeal from the United States Court of International Trade in case no. 11-CV-0140, Senior Judge Judith M. Barzilay.

______________________

JUDGMENT

______________________

N ED H. M ARSHAK , Grunfeld, Desiderio, Lebowitz, Silverman & Klestadt, LLP, of New York, New York, argued for plaintiff-appellant. With him on the brief were

R OBERT B. S ILVERMAN , J OSEPH M. S PRARAGEN and

F RANCES P. H ADFIELD

.

S TEPHEN C. T OSINI , Senior Trial Counsel, Commercial Litigation Branch, Civil Division, United States Department of Justice, of Washington, DC, argued for defendant-appellee. With him on the brief were T ONY W EST , Assistant Attorney General, J EANNE E. D AVIDSON

, Director, and P ATRICIA M. M CCARTHY , Assistant Director.

______________________T HIS C AUSE having been heard and considered, it is

O RDERED and A DJUDGED :

P ER C URIAM (P ROST

, M OORE , and O’M ALLEY

, Circuit Judges ).

AFFIRMED. See Fed. Cir. R. 36.

E NTERED BY O RDER OF THE C OURT

May 10, 2012 /s/ Jan Horbaly

Date Jan Horbaly
Clerk
<TABLE> <S> <C>


<ARTICLE>   5
<PERIOD-TYPE>                      YEAR
<FISCAL-YEAR-END>           DEC-31-1997
<PERIOD-END>                DEC-31-1997
<CASH>                          619,683
<SECURITIES>                          0
<RECEIVABLES>                   234,857
<ALLOWANCES>                     10,006
<INVENTORY>                     965,199
<CURRENT-ASSETS>              2,293,800
<PP&E>                        6,006,297
<DEPRECIATION>                3,188,079
<TOTAL-ASSETS>                5,713,830
<CURRENT-LIABILITIES>         3,616,126
<BONDS>                               0
<PREFERRED-MANDATORY>                 0
<PREFERRED>                           0
<COMMON>                        122,155
<OTHER-SE>                    1,975,549
<TOTAL-LIABILITY-AND-EQUITY>  5,713,830
<SALES>                         923,792
<TOTAL-REVENUES>              2,246,795
<CGS>                         1,028,577
<TOTAL-COSTS>                 1,028,577
<OTHER-EXPENSES>              9,307,685
<LOSS-PROVISION>                 60,905
<INTEREST-EXPENSE>                    0
<INCOME-PRETAX>              (8,949,652)
<INCOME-TAX>                          0
<INCOME-CONTINUING>          (8,949,652)
<DISCONTINUED>                        0
<EXTRAORDINARY>                       0
<CHANGES>                             0
<NET-INCOME>                 (8,949,652)
<EPS-PRIMARY>                     (0.78)
<EPS-DILUTED>                     (0.78)


</TABLE>
fzmd-ex1019_80.htm



EXHIBIT 10.19

Amendment to Purchasing Agreement
Agreement Number: 24177

Effective as of January 1, 2018, EL PASO HEALTHCARE SYSTEM, LTD., having its principal place of business at 4100 Rio Bravo, El Paso, TX 79902 (hereinafter referred to as "Division/Facility"), and CPM Medical Consultants, LLC, (hereinafter referred to as "Seller" or "Vendor"), having its principal place of business at 1565 N. Central Expressway, Suite 200, Richardson, TX 75080, hereby agree to amend their Purchasing Agreement dated April 1, 2017 for Spinal Implants (the "Agreement"), as follows:


	
 
	
1.
	
Definitions. The capitalized terms in this Amendment shall have the meaning designated in the Agreement unless otherwise expressly provided herein.





	
 
	
2.
	
Term. The term of the Agreement shall be extended to December 31, 2018.





	
 
	
3.
	
Products and Pricing. The current Exhibit A to the Agreement shall be replaced with replacement Exhibit A attached hereto and dated January 1, 2018.





	
 
	
4.
	
Except as expressly amended by this Amendment, the terms and conditions of the Agreement shall remain in full force and effect.




IN WITNESS WHEREOF, the parties hereby indicate their agreement to the terms of this Amendment by the signatures of their authorized representatives.


			
	
Division/Facility
	
 
	
Vendor

	
By:       ____________________________
	
 
	
By:       ___________________________

	
Name:  Cindy Sightes_________________
	
 
	
Name:  ___________________________

	
Title:    Division CFO_________________
	
 
	
Title:    ___________________________

	
Date:    ____________________________
	
:
	
Date  _____________________________

	
 
	
 
	
 




 

 

 

 



EXHIBIT 10.19

Exhibit A

Division: El Paso Healthcare System, LTD.

Vendor: CPM Medical Consultants, LLC

Date: January 1, 2018

Products/Services with Pricing
Johannes T. MARTIN, petitioner, v. LIVING ESSENTIALS, LLC.

No. 17-8352.

Supreme Court of the United States

Dec. 3, 2018.

Petition for rehearing denied.
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               APR-01-2000
<CASH>                                           1,640
<SECURITIES>                                         0
<RECEIVABLES>                                   11,532
<ALLOWANCES>                                     (516)
<INVENTORY>                                     10,119
<CURRENT-ASSETS>                                23,154
<PP&E>                                           4,984
<DEPRECIATION>                                 (3,409)
<TOTAL-ASSETS>                                  43,556
<CURRENT-LIABILITIES>                           12,516
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           110
<OTHER-SE>                                      30,872
<TOTAL-LIABILITY-AND-EQUITY>                    43,556
<SALES>                                         12,161
<TOTAL-REVENUES>                                12,161
<CGS>                                            6,249
<TOTAL-COSTS>                                    5,912
<OTHER-EXPENSES>                                 6,140
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                (38)
<INCOME-PRETAX>                                  (266)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                              (266)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     (266)
<EPS-BASIC>                                     (0.03)
<EPS-DILUTED>                                   (0.03)


</TABLE>
IN THE UNITED STATES DISTRICT COURT 

FOR THE EASTERN DISTRICT OF TEXAS 

MARSHALL DIVISION 

AKOUSTIS TECHNOLOGIES, INC., 

AKOUSTIS, INC., CORNELL UNIVERSITY, 

AND CORNELL RESEARCH FOUNDATION, 

INC., 

Plaintiff, 

vs. 

QORVO, INC., 

Defendant. 

Civil Action No. 2:23-cv-180-JRG-RSP 

JURY TRIAL 

ORDER ON JOINT STIPULATION OF DISMISSAL WITH PREJUDICE 

Before the Court is the Parties’ Joint Stipulation of Dismissal with Prejudice dismissing 

with prejudice all claims, counterclaims, and affirmative defenses asserted by Akoustis 

Technologies, Inc., Akoustis, Inc., Cornell University, Cornell Research Foundation, Inc., and 

Qorvo, Inc., and with each party bearing its own costs and attorneys’ fees. Having considered the 

Joint Stipulation, the Court ORDERS the dismissal with prejudice of all claims, counterclaims, 

and affirmative defenses asserted by Akoustis Technologies, Inc., Akoustis, Inc., Cornell 

University, Cornell Research Foundation, Inc., and Qorvo, Inc., and with each party bearing its 

own costs and attorneys’ fees. 

Case 2:23-cv-00180-JRG-RSP Document 156-1 Filed 12/06/24 Page 1 of 1 PageID

#: 5569
```
 
 
VIX FUTURES - CBOE FUTURES EXCHANGE                                  Code-1170E1
FUTURES ONLY POSITIONS AS OF 07/09/13                         |
--------------------------------------------------------------| NONREPORTABLE
      NON-COMMERCIAL      |   COMMERCIAL    |      TOTAL      |   POSITIONS
--------------------------|-----------------|-----------------|-----------------
  LONG  | SHORT  |SPREADS |  LONG  | SHORT  |  LONG  | SHORT  |  LONG  | SHORT
--------------------------------------------------------------------------------
($1000 X INDEX)                                      OPEN INTEREST:      335,927
COMMITMENTS
  99,938  119,503   74,536  135,037  114,041  309,511  308,080   26,416   27,847

CHANGES FROM 07/02/13 (CHANGE IN OPEN INTEREST:     34,579)
  12,240   17,045   -7,181   26,209   18,161   31,268   28,025    3,311    6,554

PERCENT OF OPEN INTEREST FOR EACH CATEGORY OF TRADERS
    29.7     35.6     22.2     40.2     33.9     92.1     91.7      7.9      8.3

NUMBER OF TRADERS IN EACH CATEGORY (TOTAL TRADERS:      161)
      44       70       76       31       33      127      136
```

----

Updated July 13, 2013
<TABLE> <S> <C>


<ARTICLE>                     5
<CIK>                         0000911167
<NAME>                        ARIEL CORPORATION
       
<S>                             <C>
<PERIOD-TYPE>                                  3-MOS
<PERIOD-END>                                   MAR-31-1998
<FISCAL-YEAR-END>                              DEC-31-1998
<CASH>                                         986,513
<SECURITIES>                                   0
<RECEIVABLES>                                  5,178,626
<ALLOWANCES>                                   202,446
<INVENTORY>                                    5,134,936
<CURRENT-ASSETS>                               11,604,389
<PP&E>                                         5,261,753
<DEPRECIATION>                                 2,997,102
<TOTAL-ASSETS>                                 14,636,311
<CURRENT-LIABILITIES>                          7,348,334
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       9,673,250
<OTHER-SE>                                     4,990,540
<TOTAL-LIABILITY-AND-EQUITY>                   14,636,311
<SALES>                                        6,276,617
<TOTAL-REVENUES>                               6,276,617
<CGS>                                          3,758,124
<TOTAL-COSTS>                                  3,758,124
<OTHER-EXPENSES>                               4,229,519
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             97,163
<INCOME-PRETAX>                                (1,798,930)
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                            (1,798,930)
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   (1,798,930)
<EPS-PRIMARY>                                  (0.19)
<EPS-DILUTED>                                  (0.17)
        


</TABLE>
COLONY COVE PROPERTIES, LLC, petitioner, v. CITY OF CARSON, CALIFORNIA, et al.

No. 18-573.

Supreme Court of the United States

Jan. 14, 2019.

*918Petition for writ of certiorari to the United States Court of Appeals for the Ninth Circuit denied.
Jesus L. ARNETT, petitioner, v. Patrick COVELLO, Acting Warden.

No. 18-6520.

Supreme Court of the United States

Jan. 7, 2019.

Petition for writ of certiorari to the United States Court of Appeals for the Ninth Circuit denied.
Exhibit 32.3








Certification of Executive Vice President and Principal Financial Officer











CERTIFICATION PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


(18 U.S.C. SECTION 1350)








In connection with the Quarterly Report of Century Casinos, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned certifies, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:





(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and





(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.














Date:  August 6, 2010








/s/ Margaret Stapleton


Margaret Stapleton


Executive Vice President and Principal Financial Officer
Exhibit 10.17


 


SECOND AMENDMENT TO 8% CONVERTIBLE
DEBENTURE:


 


This Second Amendment to the 8% Convertible Debenture,
dated September 1, 2016, as amended by First Amendment to 8% Convertible Debenture, dated September 28, 2017, made by BioLabMart
Inc., now known as Qrons Inc. for the benefit of CubeSquare LLC in the amount of $10,000 (the “Debenture”) hereby amends
the Debenture as follows:


 


The maturity date of the Debenture is hereby amended to
September 1, 2019.


 


Except as amended hereby all of the terms and
conditions of the Debenture shall remain in full force and effect.


 


 


Dated this 9th  day of September
2018


Qrons Inc. 


 


By: /s/Jonah Meer Chief Executive
Officer


 


ACKNOWLEDGED AND AGREED:


 


CubeSquare LLC


 


By: /s/Jonah Meer Managing Member
EXHIBIT 31.2 

Certifications of ChiefFinancial Officer 

I, Stephen T. Wills, certify that: 

I have reviewed this quarterly reporton Form 10-Q of Palatin Technologies, Inc.; 

Based on my knowledge, this reportdoes not contain any untrue statement of a material fact or omit to state a material factnecessary to make the statements made, in light of the circumstances under which suchstatements were made, not misleading with respect to the period covered by this report; 

Based on my knowledge, the financialstatements, and other financial information included in this report, fairly present in allmaterial respects the financial condition, results of operations and cash flows of theregistrant as of, and for, the periods presented in this report; 

The registrant’s othercertifying officer and I are responsible for establishing and maintaining disclosurecontrols and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for theregistrant and have: 

(a)              Designed such disclosure controls and procedures, or caused such disclosure          controls and procedures to be designed under our supervision, to ensure that          material information relating to the registrant, including its consolidated          subsidiaries, is made known to us by others within those entities, particularly          during the period in which this report is being prepared; 

(b)              Evaluated the effectiveness of the registrant’s disclosure controls and          procedures and presented in this report our conclusions about the effectiveness          of the disclosure controls and procedures, as of the end of the period covered          by this report based on such evaluation; and 

(c)              Disclosed in this report any change in the registrant’s internal control          over financial reporting that occurred during the registrant’s most recent          fiscal quarter that has materially affected, or is reasonably likely to          materially affect, the registrant’s internal control over financial          reporting; and 

The registrant’s othercertifying officer and I have disclosed, based on our most recent evaluation of internalcontrol over financial reporting, to the registrant’s auditors and the auditcommittee of the registrant’s board of directors: 

(a)              All significant deficiencies and material weaknesses in the design or operation          of internal control over financial reporting which are reasonably likely to          adversely affect the registrant’s ability to record, process, summarize and          report financial information; and 

(b)              Any fraud, whether or not material, that involves management or other employees          who have a significant role in the registrant’s internal control over          financial reporting. 

Date: February 9, 2005 

/s/ Stephen T. Wills            

Stephen T. Wills, ChiefFinancial Officer
Din DEVEAUX, petitioner, v. Antoine CALDWELL, Warden.

No. 17-8786.

Supreme Court of the United States

Oct. 1, 2018.

Petition for writ of certiorari to the United States Court of Appeals for the Eleventh Circuit denied.
EXHIBIT 23.1





CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS





We consent to the
incorporation by reference in the Registration Statements (Form S-8) pertaining to the Amended and Restated 1993 Stock Plan (Nos. 33-75390, 33-87420, 333-44097, 333-92425, 333-52370 and 333-75410) and the Employee Stock Purchase Plan (Nos. 33-75392
and 333-18519) of Neurobiological Technologies, Inc. of our report dated August 9, 2002, with respect to the financial statements of Neurobiological Technologies, Inc. included in the Annual Report (Form 10-K) for the year ended June 30, 2002.





LOGO


Palo Alto, California


September 26, 2002